Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 28, 2009

AstraZeneca to Help UCB Launch RA/Crohn’s Drug in Brazil

  • AstraZeneca has taken on Brazilian rights to UCB’s Cimzia®, approved in the U.S. for rheumatoid arthritis (RA) and Crohn’s disease. AstraZeneca may also distribute line extensions related to Cimzia in Brazil, while UCB retains the right to co-promote Cimzia and line extensions in the country.

    UCB is developing Cimzia in other autoimmune disease like lupus as well as fracture healing and post-menopausal osteoporosis. The drug is at the Phase II stage for all indications.

    AstraZeneca is responsible for registration and upon approval will be the exclusive distributor of Cimzia, an PEGylated anti-TNF alpha compound in Brazil. Initial registration activities will focus on RA and Crohn’s.

     



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »